Urgent Desire To Urinate — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for urgent desire to urinate. 12 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
12
Active US patents
74/100
Avg vulnerability
—
Annual revenue covered

Originators in Urgent Desire To Urinate

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer 12 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating urgent desire to urinate. Each bar = one year. Y-axis scaled to peak year (12 patents).

12
27

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Toviaz
Fesoterodine Fumarate
 Pfizer 12 74 — 2027-06-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7807715 Toviaz method of use 80 2027-06-07
8088398 Toviaz method of use 80 2027-06-07
7807715 Toviaz method of use 80 2027-06-07
8088398 Toviaz method of use 80 2027-06-07
7807715 Toviaz other 75 2027-12-07
8088398 Toviaz other 75 2027-12-07
8088398 Toviaz other 75 2027-12-07
8501723 Toviaz other 75 2027-12-07
8501723 Toviaz other 75 2027-12-07
7807715 Toviaz other 75 2027-12-07

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8501723 Toviaz formulation 60 2027-06-07
8501723 Toviaz formulation 60 2027-06-07
8088398 Toviaz other 75 2027-12-07
8501723 Toviaz other 75 2027-12-07
7807715 Toviaz other 75 2027-12-07
8088398 Toviaz other 75 2027-12-07
8501723 Toviaz other 75 2027-12-07
7807715 Toviaz other 75 2027-12-07
8088398 Toviaz method of use 80 2027-06-07
7807715 Toviaz method of use 80 2027-06-07

Related